Send to

Choose Destination
Nat Immunol. 2015 Jun;16(6):609-17. doi: 10.1038/ni.3159. Epub 2015 Apr 27.

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

Author information

Division of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany.
1] Division of Translational Immunology, German Cancer Research Center, Heidelberg, Germany. [2] Regensburg Center for Interventional Immunology, University Clinic and University of Regensburg, Regensburg, Germany.


Tumor-associated eosinophilia is frequently observed in cancer. However, despite numerous studies of patients with cancer and mouse models of cancer, it has remained uncertain if eosinophils contribute to tumor immunity or are mere bystander cells. Here we report that activated eosinophils were essential for tumor rejection in the presence of tumor-specific CD8(+) T cells. Tumor-homing eosinophils secreted chemoattractants that guided T cells into the tumor, which resulted in tumor eradication and survival. Activated eosinophils initiated substantial changes in the tumor microenvironment, including macrophage polarization and normalization of the tumor vasculature, which are known to promote tumor rejection. Thus, our study presents a new concept for eosinophils in cancer that may lead to novel therapeutic strategies.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center